1. Home
  2. ALAR vs XCUR Comparison

ALAR vs XCUR Comparison

Compare ALAR & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alarum Technologies Ltd.

ALAR

Alarum Technologies Ltd.

HOLD

Current Price

$1.87

Market Cap

12.5M

Sector

Technology

ML Signal

HOLD

XCUR

Exicure Inc.

HOLD

Current Price

$1.34

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALAR
XCUR
Founded
2013
2011
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.5M
13.7M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
ALAR
XCUR
Price
$1.87
$1.34
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$14.00
N/A
AVG Volume (30 Days)
146.7K
242.7K
Earning Date
05-28-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
83.37
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$24.51
N/A
Revenue Next Year
$33.43
N/A
P/E Ratio
$44.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.62
$1.27
52 Week High
$18.00
$9.48

Technical Indicators

Market Signals
Indicator
ALAR
XCUR
Relative Strength Index (RSI) 25.52 27.41
Support Level $1.62 N/A
Resistance Level $7.54 $2.02
Average True Range (ATR) 0.13 0.16
MACD 0.24 -0.01
Stochastic Oscillator 53.06 4.62

Price Performance

Historical Comparison
ALAR
XCUR

About ALAR Alarum Technologies Ltd.

Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.

About XCUR Exicure Inc.

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Share on Social Networks: